[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589528":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":48,"collaborators":32,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":32,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":32,"enrollmentInfo":60,"targetDuration":32,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":74,"whyStopped":32,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University Hospital Sestre Milosrdnice","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Proluxx Treatment Group","EXPERIMENTAL","Group that will use topical artificial tear spray applied to closed eyelids four times daily for 28 days.",[13],"Device: Proluxx Artificial Tear Spray",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Proluxx Artificial Tear Spray","Topical artificial tear spray applied to closed eyelids four times daily for 28 days.",[9],[21],"Proluxx Duo sprej za oko",[23],{"name":24,"affiliation":25,"role":26},"Ivanka Petric Vicković, Prof,MD,PHD","Eye Department of UHC Sestre milosrdnice Zagreb","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Danijel Mikulić, MD","CONTACT","00385989956997",null,"danijel.mikulic@kbcsm.hr",[35],{"facility":36,"status":32,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":32},"UHC Sestre milosrdnice","Zagreb","City of Zagreb","10000","Croatia","HR",{"type":43,"coordinates":44},"Point",[45,46],15.97798,45.81444,{"lat":46,"lon":45},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Danijel Mikulic","MD","100589528","efficacy-of-lipid-containing-artificial-tears-in-the-treatment-of-dry-eye-100589528",false,"NCT06955585","Efficacy of Lipid-containing Artificial Tears in the Treatment of Dry Eye","Inclusion Criteria:\n\n* Ocular Surface Disease Index (OSDI) score between 14 and 50 and at least one positive diagnostic test: tear break-up time (TBUT) \\\u003C7 seconds, Schirmer I test (≤10 mm\u002F5 min), or positive corneal staining based on the Oxford grading scheme. In addition, participants must not have used artificial tears for at least two weeks prior to enrollment, even if they were previously on such therapy\n\nExclusion Criteria:\n\n* use of systemic or topical corticosteroids, active ocular infection, or ocular surgery within the last 3 months","ALL","18 Years",{"count":61,"type":62},50,"ESTIMATED","INTERVENTIONAL",[65],"NA","This clinical study involves patients with Dry Eye Disease (DED) who are visiting an ophthalmology outpatient clinic. Eligible participants must have an Ocular Surface Disease Index (OSDI) score ≥14 and \\\u003C50, and at least one positive diagnostic test: tear break-up time (TBUT) \\\u003C7 seconds, Schirmer I test \\\u003C10 mm\u002F5 min, or positive corneal staining based on the Oxford grading scale. At baseline, tear film thickness will be measured using Pentacam imaging. Participants will then receive Proluxx eye spray, applied four times daily for 28 days. After this treatment period, a follow-up examination with all baseline assessments will be repeated.",[68,69,70],"Dry Eye Disease","Dry Eye","Dry Eye, Evaporative",[72,73],"dry eye","artificial tears","NOT_YET_RECRUITING","2025-04-24",{"date":77,"type":78},"2025-05-02","ACTUAL",{"date":80,"type":62},"2025-04-25",{"date":82,"type":62},"2025-09",{"name":5,"class":6},1]